Tirzepatide

The most effective GLP-1 medication is now available in a multi-dose pen NEW YORK, April 2, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced that it is working with Eli Lilly to launch the recently FDA-approved Zepbound® (tirzepatide) KwikPen® nationwide on its platform. The prefilled, multi-dose pen offers a convenient way for patients to take the most effective GLP-1 medication available. Patients can visit Ro.co to access the KwikPen along with ongoing high-quality clinical care, including 24/7 messaging, 1-1 coaching, educational content, weight tracking and dose logging, side-effect monitoring, and more. Continue Reading Zepbound KwikPen now on Ro "By working with Eli Lilly to make the KwikPen accessible on Ro's platform, we're continuing to help patients access the latest treatments, in the most innovative form factors, at the lowest possible cost," said Zach Reitano, co-founder and CEO of Ro. Ro connected its platform with Eli Lilly's direct-to-patient offering in December 2024 to expand access to FDA-approved, authentic Zepbound. Ro has since played a key role in bringing new Zepbound treatment delivery options to market faster while ensuring patients can access them at the lowest available cash pay price. The Zepbound KwikPen is available to cash-pay patients with upfront, transparent pricing. Monthly pricing starts at $299 for the 2.5 mg starter dose and $399 for the 5 mg dose. For higher doses (7.5 mg, 10 mg, 12.5 mg, and 15 mg), eligible patients can access manufacturer discounted pricing of $449 per month when refills are completed within 45 days of their previous delivery. Patients interested in checking their insurance coverage can use Ro's GLP-1 Insurance Checker -- a free tool that has helped over 2 million people understand their benefits and get their medication at the lowest possible price – whether that's using insurance coverage or paying cash. For more information on Ro's membership and full suite of GLP-1 options, visit About Ro Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the easiest, most effective care possible. Ro is the only company to offer nationwide telehealth, labs, and pharmacy services. This is enabled by Ro's vertically integrated platform that helps patients achieve their goals through a convenient, end-to-end healthcare experience spanning from diagnosis, to delivery of medication, to ongoing care. Since 2017, Ro has helped millions of patients in nearly every single county in the United States, including 99% of primary care deserts. Visit Ro.co for more information. Contact: [email protected] SOURCE Ro 21% more press release views with Request a Demo